Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

biopharma

RemeGen’s $4.2 billion licensing deal falls flat with investors

RemeGen’s $4.2 billion licensing deal falls flat with investors

The biopharma firm had fanned excitement over a rights deal for its autoimmune drug but the eventual terms, with just a small portion of upfront cash, left the market disappointed…
July 10, 2025
9995.HK 688331.SHG
Clover Biopharmaceuticals Ltd. faces a potentially damaging fight

Dispute over Covid vaccines casts doubt on Clover Bio recovery

The Chinese biopharma firm faces a potentially damaging fight over a $224 million upfront payment it received in an ill-fated deal to supply Covid vaccines Key Takeaways: The Gavi international…
April 3, 2025
2197.HK
BeiGene

BeiGene heads for profit milestone after hemorrhaging cash

With a blockbuster drug under its belt and another product approved for U.S. sale, the biopharma firm says it is on track to post an annual operating profit this year…
January 24, 2025
6160.HK ONC.US 688235.SHG

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat

Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list…
May 6, 2022

Recent Articles

RemeGen’s $4.2 billion licensing deal falls flat with investors
July 10, 2025

RemeGen’s $4.2 billion licensing deal falls flat with investors

9995.HK 688331.SHG
April 3, 2025

Dispute over Covid vaccines casts doubt on Clover Bio recovery

2197.HK
January 24, 2025

BeiGene heads for profit milestone after hemorrhaging cash

6160.HK ONC.US 688235.SHG
May 6, 2022

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat

RELATED ARTICLES

  1. RemeGen as problems and losses pile up
    March 13, 2025
    No respite for RemeGen as problems and losses pile up
    9995.HK 688331.SHG
  2. April 3, 2025
    Dispute over Covid vaccines casts doubt on Clover Bio recovery
    2197.HK
  3. May 29, 2025
    3SBio hits the big time with $6 billion cancer drug deal
    1530.HK
  4. June 12, 2025
    CSPC Pharma teases big bucks deals after earnings miss
    1093.HK
  5. July 3, 2025
    HBM notches up another mega deal but is the model sustainable?
    2142.HK
  6. June 19, 2025
    Alphamab stake sale could signal harder times ahead
    9966.HK
  7. March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.